FindTrial
Sign In

Comparison between vildagliptin and glimepiride on fatty acid binding protein-4 and lipocalin-2 levels.

EFFECT OF VILDAGLIPTIN AND GLIMEPIRIDE ON FATTY ACID- BINDING PROTEIN-4 (FABP -4) AND LIPOCALIN-2 LEVELS IN TYPE-2 DIABETES MELLITUS OBESE PATIENTS INADEQUATELY CONTROLLED ON METFORMIN MONOTHERAPY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/11/016326
Enrollment
60
Registered
2018-11-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Vildagliptin: Class - Anti Hyperglycemic agent Dose - 100 mg/day Route- Oral Total duration of therapy- 12 weeks Control Intervention1: Glimepiride: Class - Anti Hyperglycemic agent Do

Sponsors

University College Of Medical Sciences and GTB hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with type 2 diabetes mellitus and obesity (BMI>=25 Kg/m2) who are on metformin monotherapy for at least three months at the maximum recommended dose (2000mg/day) and having inadequately controlled glycemic parameter with metformin monotherapy. 2.Patients of either sex with age between 30 -60 years. 3.Patients/guardian willing to give written informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with an active infectious disease. 2. Patients suffering from a neuropsychiatric illness like depression 3.Patients with renal or liver dysfunction. 4.Patients with a history of cardiopathies, malignancy or autoimmune diseases. 5.Patients with a history of recent acute myocardial infarction (within last three months). 6.Patients with a history of major surgical operation in the last three months. 7.Patients with any disease-producing inflammation. 8.Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
1.Changes in serum levels of FABP-4 and Lipocalin-2 before and after 12 weeks of treatment with vildagliptin and glimepiride 2.Changes in blood sugar levels, HbA1c, HOMA-IR index and anthropometric measures before and after 12 weeks of treatment with vildagliptin and glimepiride. Timepoint: 12 weeks of treatment—

Secondary

MeasureTime frame
Changes in blood sugar levels, HbA1c, HOMA-IR index and anthropometric measures before and after 12 weeks of treatment with vildagliptin and glimepiride. Timepoint: 12 weeks of treatment—

Countries

India

Contacts

Public ContactDr Seema Jain

University College Of Medical Sciences and GTB hospital

dr.seemajain@gmail.com9910412070

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026